Page 2 - ப்வெர்டோ ரிக்கோ கூட்டமைப்பு க்கு மருத்துவ விசாரணை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்வெர்டோ ரிக்கோ கூட்டமைப்பு க்கு மருத்துவ விசாரணை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்வெர்டோ ரிக்கோ கூட்டமைப்பு க்கு மருத்துவ விசாரணை Today - Breaking & Trending Today

PAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals

PAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals
News provided by
Share this article
Share this article
SANDUSKY, OH, Jan. 14, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today published a management outlook for 2021 on the company s strategy to develop and monetize the cannabis assets acquired last year. The strategic outlook is included in its entirety below:
PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook
PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications as is the case with opioid based treatments.
Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis. ....

United States , Puerto Rico , Jim Diprima , Puration Inc , Veristat Inc , Alkame Holdings Inc , Drug Administration , Group Inc , Puerto Rico Consortium For Clinical Investigation , Securities Exchange , Extracts Inc , Biopharmaceutical Strategic , Chronic Obstructive Pulmonary Disorder , Investigational New Drug , Puerto Rico Consortium , Clinical Investigation , Alkame Holdings , Looking Statements , Securities Act , Securities Exchange Act , Pao Group , ஒன்றுபட்டது மாநிலங்களில் , ப்வெர்டோ ரிக்கோ , ஜிம் டிப்ரிமா , குழு இன்க் , ப்வெர்டோ ரிக்கோ கூட்டமைப்பு க்கு மருத்துவ விசாரணை ,

PAO Group, Inc.: PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook

PAO Group, Inc.: PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook
Sandusky, Ohio (Newsfile Corp. - January 14, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today published a management outlook for 2021 on the company s strategy to develop and monetize the cannabis assets acquired last year. The strategic outlook is included in its entirety below:
PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook
PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications as is the case with opioid based treatments.
Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis. ....

United States , Puerto Rico , Kostenloser Wertpapierhandel , Jim Diprima , Puration Inc , Veristat Inc , Alkame Holdings Inc , Drug Administration , Group Inc , Puerto Rico Consortium For Clinical Investigation , Securities Exchange , Extracts Inc , Ohio Newsfile Corp , Biopharmaceutical Strategic , Chronic Obstructive Pulmonary Disorder , Investigational New Drug , Puerto Rico Consortium , Clinical Investigation , Alkame Holdings , Looking Statements , Securities Act , Securities Exchange Act , ஒன்றுபட்டது மாநிலங்களில் , ப்வெர்டோ ரிக்கோ , ஜிம் டிப்ரிமா , குழு இன்க் ,

PAO Group, Inc.: PAOG Develops CBD Nutraceutical for $12.7 Billion from Patented Extract Process

PAO Group, Inc.: PAOG Develops CBD Nutraceutical for $12.7 Billion from Patented Extract Process
Sandusky, Ohio (Newsfile Corp. - December 18, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced the company expects to generate its first revenue next year in 2021 from its Cannabidiol (CBD) extraction technology, RespRx, acquired in July of this year, 2020.
Yesterday, PAOG announced an engagement with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary CBD extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
PAOG, through its engagement with PRCCI, expects to rapidly produce its CBD COPD Nutraceutical product and establish sales. Grand View Research forecasts the CBD Nutraceutical marketplace reaching a value of $12.7 billion by 2025. ....

Puerto Rico , Kostenloser Wertpapierhandel , Jim Diprima , Puration Inc , Alkame Holdings Inc , Group Inc , Puerto Rico Consortium For Clinical Investigation , View Research , Securities Exchange , Ohio Newsfile Corp , Extracts Inc , Puerto Rico Consortium , Clinical Investigation , Chronic Obstructive Pulmonary Disorder , Alkame Holdings , Looking Statements , Securities Act , Securities Exchange Act , ப்வெர்டோ ரிக்கோ , ஜிம் டிப்ரிமா , குழு இன்க் , ப்வெர்டோ ரிக்கோ கூட்டமைப்பு க்கு மருத்துவ விசாரணை , பார்வை ஆராய்ச்சி , பத்திரங்கள் பரிமாற்றம் , சாறுகள் இன்க் , ப்வெர்டோ ரிக்கோ கூட்டமைப்பு ,

PAOG Announces Puerto Rico Consortium For Clinical Investigation Engagement To Advance CBD COPD Nutraceutical Care Solution

PAOG Announces Puerto Rico Consortium For Clinical Investigation Engagement To Advance CBD COPD Nutraceutical Care Solution
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.

Puerto Rico , United States , Jim Diprima , Puration Inc , Alkame Holdings Inc , Group Inc , Puerto Rico Consortium For Clinical Investigation , Newsfile Corp , Securities Exchange , Ohio Newsfile Corp , Extracts Inc , Puerto Rico Consortium , Clinical Investigation , Chronic Obstructive Pulmonary Disorder , Alkame Holdings , Looking Statements , Securities Act , Securities Exchange Act , ப்வெர்டோ ரிக்கோ , ஒன்றுபட்டது மாநிலங்களில் , ஜிம் டிப்ரிமா , குழு இன்க் , ப்வெர்டோ ரிக்கோ கூட்டமைப்பு க்கு மருத்துவ விசாரணை , பத்திரங்கள் பரிமாற்றம் , சாறுகள் இன்க் , ப்வெர்டோ ரிக்கோ கூட்டமைப்பு ,

PAOG Targets First Revenue From $12.7 Billion Market Selling CBD COPD Nutraceutical Care Product Line

Share this article
Share this article
SANDUSKY, Ohio, Dec. 18, 2020 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today announced the company expects to generate its first revenue next year in 2021 from its Cannabidiol (CBD) extraction technology, RespRx, acquired in July of this year, 2020.
Yesterday, PAOG announced an engagement with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary CBD extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
PAOG, through its engagement with PRCCI expects to rapidly produce its CBD COPD Nutraceutical product and establish sales. Grand View Research forecasts the CBD Nutraceutical marketplace reaching a value of $12.7 billion by 2025. ....

United States , Puerto Rico , Jim Diprima , Puration Inc , Puerto Rico Consortium For Clinical Investigation , View Research , Alkame Holdings Inc , Securities Exchange , Extracts Inc , Group Inc , Puerto Rico Consortium , Clinical Investigation , Chronic Obstructive Pulmonary Disorder , Grand View Research , Alkame Holdings , Looking Statements , Securities Act , Securities Exchange Act , ஒன்றுபட்டது மாநிலங்களில் , ப்வெர்டோ ரிக்கோ , ஜிம் டிப்ரிமா , ப்வெர்டோ ரிக்கோ கூட்டமைப்பு க்கு மருத்துவ விசாரணை , பார்வை ஆராய்ச்சி , பத்திரங்கள் பரிமாற்றம் , சாறுகள் இன்க் , குழு இன்க் ,